The CANTOS trial—testing the use of IL-1β-specific antibody treatment in patients with previous myocardial infarction—has clearly highlighted the relevance of residual inflammatory risk and demonstrated the potential of anti-inflammatory therapies to prevent recurrent ischaemic events25. This evidence concerns the gene IL1B and myocardial infarction.